Navigation Links
Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research

New data on Eloxatin(R), Taxotere(R) and on three investigational agents (VEGF Trap, S-1 and TroVax(R)) will be presented at the 43rd annual ASCO meeting

BRIDGEWATER, N.J., May 29, 2007 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that a total of 375 abstracts indicative of its oncology commitment have been accepted for the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois (June 1-5, 2007). The results from key studies involving the company's leading anticancer agents, Eloxatin(R) (oxaliplatin injection) and Taxotere(R) (docetaxel injection concentrate), will be presented alongside clinical trial data examining investigational agents, aflibercept (VEGF Trap), S-1 (oral fluoropyrimidine) and TroVax(R) (Therapeutic Cancer Vaccine).

Of the abstracts which have been accepted, 129 focus on Eloxatin(R), 214 on Taxotere(R), 29 on S-1, two on VEGF Trap and one on TroVax(R). One hundred and ninety three Eloxatin(R) and Taxotere(R) abstracts were also accepted for presentation at the scientific sessions, with five Eloxatin(R) and 15 Taxotere(R) abstracts to be oral communications, including one Eloxatin(R) presentation at the ASCO plenary session.

The key results presented with Eloxatin(R)-based treatment (in combination with 5FU/LV) cover clinical trials in the adjuvant (post-surgery) colon cancer (MOSAIC study) and the metastatic (advanced) colorectal cancer (NCCTG/N9741study, EORTC40983/EPOC study) settings.

Data looking at Taxotere(R)-based regimens in adjuvant and in metastatic breast cancer will be presented during the meeting.

Two phase II studies examined aflibercept (VEGF Trap) as a single agent in recurrent ovarian and lung cancers. VEGF Trap is an anti-angiogenic agent that blocks the Vascular Endothelial Growth Factor (VEGF), and is currently being investigated to assess its use in stopping tumor growth. Aflibercept is in phase
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:3/6/2015)... Washington , 6. März 2015 /PRNewswire/ ... von Röntgenstrahlen, feierte auf dem European Congress ... , Österreich, die 1.000. Installation seines ... Logo - http://photos.prnewswire.com/prnh/20150304/179432LOGO ... Dosimeter, der in Echtzeit Informationen über die ...
(Date:3/6/2015)... Calif. , March 6, 2015  Abaxis, Inc. ... manufacturing point-of-care instruments and consumables for the medical, research, ... to the veterinary and research markets in ... Center for Veterinary Biologicals of the U.S. Department of ... Kit for the detection of   A. phagocytophelium ...
(Date:3/6/2015)... Troyen A. Brennan, M.D., M.P.H., Executive Vice ... CVS ), will speak before the National ... today.  Brennan will outline ways pharmacy care ... cost and quality as the overall health care system ... pharmacy chain to stop selling tobacco in support of ...
Breaking Medicine Technology:Unfors RaySafe, ein Unternehmen von Fluke Biomedical, feiert 1.000. Installation seines Systems zur Echtzeit-Strahlendosimetrie 2Unfors RaySafe, ein Unternehmen von Fluke Biomedical, feiert 1.000. Installation seines Systems zur Echtzeit-Strahlendosimetrie 3Abaxis, Inc. Announces USDA Clearance of VetScan Anaplasma Rapid Test 2Abaxis, Inc. Announces USDA Clearance of VetScan Anaplasma Rapid Test 3CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 2CVS Health Chief Medical Officer to Address National Business Group on Health on Value of Pharmacy Care in Evolving Health Care System 3
... Inc. (Nasdaq: KIPS ) announced today the pricing ... its common stock at a price of $8.00 per share. ... 2011 on the NASDAQ Global Market under the ticker symbol ... place on February 16, 2011.  The Company has granted the ...
... 2011 Bionovo, Inc. (Nasdaq: BNVI ), ... of safe and effective treatments for women,s health and ... action for 2011 in the development of MF101 (Menerba™). ... the company,s website. "Having positive clinical ...
Cached Medicine Technology:Kips Bay Medical, Inc. Announces Pricing of its Initial Public Offering of Common Stock 2Bionovo Announces 2011 Plan of Action on MF101 (Menerba™) 2Bionovo Announces 2011 Plan of Action on MF101 (Menerba™) 3Bionovo Announces 2011 Plan of Action on MF101 (Menerba™) 4
(Date:3/6/2015)... 06, 2015 Ticket Down is a reputable ... at the Moda Center. After being away from ... is showing no signs of letting up on his “Garth ... and his wife, Trisha Yearwood, to venues around the United ... their critically acclaimed tour to the Moda Center in Portland, ...
(Date:3/6/2015)... As the Muscular Dystrophy Association continues to enhance its ... two new Scientific Program Officers, Amanda Haidet-Phillips, Ph.D and ... Pavlath, Ph.D, who joined MDA late last year as ... will lead MDA as it accelerates new front-line discovery ... of neuromuscular and motor neuron diseases. , ...
(Date:3/6/2015)... CA (PRWEB) March 06, 2015 US ... of three Maryland camps – two non-contact specialty camps ... be run by Perfect Performance Training, located at Bowie ... focus on developing position specific skills, speed and strength ... hosted at Salisbury University with Marvin Graves, former quarterback ...
(Date:3/6/2015)... Bakersfield, California (PRWEB) March 06, 2015 ... $5.7 million jury verdict on March 5, 2015 in ... County. According to court documents, a jury of 12 ... she suffered from being implanted with an Ethicon TVT ... of nine men and three women also awarded $5 ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Jvion, ... the release of a Clostridium Difficile (C Diff) ... The C Diff use case is the latest ... span hospital acquired infections, chronic conditions, and individual ... the C Diff solution flags at risk individuals ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2
... that absorbs blue light has been linked to sleep disorders in ... 1 issue of the journal Sleep . As this type ... insomnia. "The strong link between lens yellowing and age could ... said Line Kessel, M.D., Ph.D., the study,s lead author. In ...
... of the speech information rate of seven languages concludes ... which languages are spoken, but much less variation in ... "A cross-linguistic perspective on speech information rate," to be ... journal Language , is co-authored by Franois Pellegrino, ...
... HealthDay Reporter , WEDNESDAY, Aug. 31 (HealthDay ... records instead of paper files could greatly improve care ... "did better and improved faster" at various kinds of ... author Dr. Randall D. Cebul, a professor of medicine ...
... WEDNESDAY, Aug. 31 (HealthDay News) -- Some breast cancer patients ... can skip hormone therapy without increasing their risk of death, ... had tumors that were hormone-receptor positive, which means they require ... tumors is designed to starve the breast cancer cells by ...
... modified a toxic chemical produced by tiny marine microbes and ... Writing today in ACS Medicinal Chemistry Letters , UF ... of marine cyanobacteria and made it more specifically toxic ... of the compound to mice with a form of colon ...
... an easy way to improve your health: trust your neighbors. ... that increasing trust in neighbors is associated with better self-reported ... where one fits into the income distribution in their local ... self-rated health," said Eileen Bjornstrom, an assistant professor of sociology ...
Cached Medicine News:Health News:Aging eyes linked to sleepless nights, new study shows 2Health News:Language speed versus efficiency: Is faster better? 2Health News:Electronic Medical Records Might Boost Diabetes Care 2Health News:Electronic Medical Records Might Boost Diabetes Care 3Health News:Some Older Breast Cancer Patients Can Skip Hormone Therapy: Study 2Health News:Some Older Breast Cancer Patients Can Skip Hormone Therapy: Study 3Health News:UF medicinal chemists modify sea bacteria byproduct for use as potential cancer drug 2Health News:UF medicinal chemists modify sea bacteria byproduct for use as potential cancer drug 3Health News:Trust in your neighbors could benefit your health, MU study shows 2
RIA kit for Insulin (liquid phase separation)....
... (17alpha-OH-P) is a steroid produced in the ... defined physiological role except as a precursor ... be converted to cortisol by the sequential ... the adrenal glands and ovaries, 17alpha-OH-P can ...
... The Helmer PC900 platelet ... to your laboratory counter top. ... smaller institution to have the ... temperature environment without taking up ...
Mini-Incubator PC100 is compact. It is the perfect solution for small institutions, mobile units, surgery rooms....
Medicine Products: